+41 91 682 20 40 info@elixi-int.com

ABOUT US

We are a Swiss pharmaceutical wholesaler, specialized in sourcing and delivering pharma products, medical devices and drugs from and to all over the world.

Here in ELIXI we consider fast delivery of life-saving medicines as a basic but mandatory human value.

 

QUALITY

As a pharmaceutical wholesaler, working directly with pharma manufactures, medicine distributors, hospitals and clinics, we comply with the newest Standard Operating Procedures (SOPs), which guide our professional team step-by-step in all of ELIXI’s activities ensuring the highest quality standards required by the pharma world.

> Read more

 

WHO WE ARE

We deliver pharma products from Switzerland and from all over the world.

Our team in ELIXI International has a solid experience in the distribution of medical products.

History has taught us to prioritize the urgency that lays behind the need of supplying a drug in the fastest possible way. Here in ELIXI we consider fast delivery as a basic but mandatory human value. In order to achieve this goal, we developed a simple but qualified process made of synergies with long lasting partners who, like us, believe in people and not in machines.

 

NEWS

Ema’s positive opinion on Hefiya (adalimumab), biosimilar to Humira.

On 31 May 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing…

read more

New indication approval for Keytruda (pembrolizumab)

On June 12, 2018, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck and Co. Inc.) for patients with recurrent…

read more

EMA recommends Sandoz’s Halimatoz (Adalimumab) for approval.

On 31 May 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing…

read more

FDA Approves Genentech’s Rituxan (Rituximab) for Pemphigus Vulgaris

Genentech, a member of the Roche Group announced that the U.S. Food and Drug Administration (FDA) has approved Rituxan (rituximab) for…

read more

EU positive opininion on Rxulti (brexpiprazole) for the treatment of Schizophrenia

On 31 May 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing…

read more

FDA Approves OLUMIANT (baricitinib) 2-mg Tablets for the Treatment of Adults with Moderately-to-Severely Active Rheumatoid Arthritis

Eli Lilly and Company and Incyte Corporation have announced that the U.S. Food and Drug Administration (FDA) has approved the 2-mg dose of…

read more

New medicine for hereditary rare disease: Tegsedi (Inotersen) addresses unmet medical need for treatment of hereditary transthyretin amyloidosis

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation in the European Union (EU)…

read more

Xeljanz (tofacitinib), first oral medication approved for moderately to severely active ulcerative colitis

The U.S. Food and Drug Administration has expanded the approval of Xeljanz (tofacitinib) to include adults with moderately to severely…

read more

UCB Announces the Approval of CIMZIA (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis

The U.S. Food and Drug Administration (FDA) has approved extending the label for CIMZIA (certolizumab pegol) to include a new indication…

read more

The European Commission has approved Novartis unit Sandoz’ Zessly ( Infliximab) a biosimilar version of Johnson & Johnson and Merck’s Remicade.

Sandoz, a Novartis division and the global leader in biosimilars, today announced that the European Commission (EC) has approved Zessly (infliximab)…

read more

Amgen receives FDA approval to expand use of Prolia (denosumab) to patients with Glucocorticoid-Induced Osteoporosis

US regulators have approved a new indication for Amgen’s Prolia, allowing its use to treat glucocorticoid-induced osteoporosis (GIOP) in men…

read more

EU approves Repatha ( Evolocumab) for reduction of CV risk

The European Commission has expanded the scope of Amgen’s PCSK9 inhibitor Repatha ( evolocumab) to include the reduction of cardiovascular…

read more

CONTACT US

ELIXI International SA

Piazza Boffalora 4
6830 Chiasso / Switzerland

Tel: +41 91 682 20 40

Your name (required)

Your e-mail (required)

Your message

captcha